|Bid||33.23 x 800|
|Ask||33.30 x 800|
|Day's Range||32.15 - 33.40|
|52 Week Range||31.79 - 56.40|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||11.94|
|Earnings Date||Feb 21, 2022 - Feb 25, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.95|
Subscribe to Yahoo Finance Plus to view Fair Value for HALOLearn more
In this article, we discuss the 15 best stocks to buy for 2022 according to analysts. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Stocks to Buy for 2022 According to Analysts. Even as inflation concerns overshadow an otherwise strong post-pandemic economic recovery towards the end […]
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with Kyprolis® (carfilzomib) and dexamethasone (Kd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. This approval follows Janssen's regulatory submission to the FDA in February 2021.